BATM Advanced Communications Ld First commercial agreement for Ador (9134Y)

TIDMBVC

RNS Number : 9134Y

BATM Advanced Communications Ld

07 January 2020

LEI: 213800FLQUB9J289RU66

7 January 2020

BATM Advanced Communications Limited

("BATM" or "the Group")

First Commercial Agreement for Ador Diagnostics

Molecular diagnostics subsidiary receives order for meningitis testing

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that Ador Diagnostics ("Ador"), the Group's subsidiary focused on the development and marketing of unique in-vitro molecular diagnostics solutions, has received its first commercial order from the leading Italian distributor of molecular biology and genomics products. Under the agreement, Ador will deliver the new NATlab reader and cartridges for the identification of meningitis in the second half of 2020.

Ador's NATlab molecular biology solution provides rapid sample-to-answer diagnosis of bacterial, viral or fungal infections, within approximately 15-90 minutes, using DNA sampling. The unique system is modular, compact and mobile, and is designed to be used at the point-of-care as well as in hospital labs. The Group believes that NATlab will allow medical practitioners to provide far quicker and more efficient treatment.

This first commercial order for the new system follows extensive lab testing and the award of over 40 global patents, including in Europe and the US, with more pending. The first models of NATlab are expected to go into final trials in leading hospitals in the first half of this year, with the initial system having been already delivered this month.

Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are delighted that Ador has received the first commercial order for the NATlab system, which is an important milestone. Meningitis is a leading infectious cause of childhood death - and speed of identification and treatment is vital. We are proud that our rapid sample-to-answer solution will help medical practitioners to quickly and efficiently diagnose the specific infection and administer the required treatment.

"We believe NATlab will transform the infectious disease diagnostics market and we have already received extremely positive feedback and significant interest from several leading medical institutions that are testing the solution. Ador is also working alongside prominent academic and research institutions, including in the UK, to develop more panels for the identification of further diseases. We look forward to reporting on Ador's progress."

Enquiries:

 
BATM Advanced Communications 
Dr Zvi Marom, Chief Executive Officer                           [phone] 
Moti Nagar, Chief Financial Officer 
 
 
Shore Capital 
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory) 
 Henry Willcocks (Corporate Broking)                            [phone] 
 
 
Luther Pendragon 
Harry Chathli, Claire Norbury, Rachel So                        [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRFFFFILVIRIII

(END) Dow Jones Newswires

January 07, 2020 02:00 ET (07:00 GMT)